Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | GMNN | O75496 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.34 |
| ▸ | SHBG | P04278 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | MMP2 | P08253 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12517981 | 0.87 | — | — | |
| SCHEMBL1077444 | 0.78 | TP53 (0.50) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL9254730 | 0.78 | TP53 (0.50) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL28204907 | 0.78 | TP53 (0.50) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL2712401 | 0.74 | TP53 (0.46) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL4306422 | 0.74 | — | — | |
| SCHEMBL622244 | 0.74 | — | — | |
| SCHEMBL15352983 | 0.72 | TSHR (0.45) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL9493197 | 0.72 | TP53 (0.50) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL8458992 | 0.72 | TP53 (0.50) | TP53KDM4EGMNNLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7230145-B2 | Catalyst for producing both end-hydroxyl group-terminated diols, process for producing the catalyst, process for producing the diols by using the catalyst, and both end-hydroxyl group-terminated diols obtained by the process | SHOWA DENKO K.K. (JP) | 2007-06-12 | — | — | US | disclosed |
| US-20040236156-A1 | Catalyst for producing both end-hydroxyl group-terminated diols, process for producing the catalyst, process for producing the diols by using the catalyst, and both end-hydroxyl group-terminated diols obtained by the process | SHOWA DENKO K.K. | 2004-11-25 | — | — | US | disclosed |
| US-20030119666-A1 | Catalyst for producing both end-hydroxyl group-terminated diols, process for producing the catalyst, process for producing the diols by using the catalyst, and both end-hydroxyl group-terminated diols obtained by the process | KADOWAKI YASUSHI (JP) | 2003-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040236156-A1 | Catalyst for producing both end-hydroxyl group-terminated diols, process for producing the catalyst, process for producing the diols by using the catalyst, and both end-hydroxyl group-terminated diols obtained by the process | ADH1C, ADH1A, EPHX2 | TP53 4164/4885KDM4E 513/4885GMNN 464/4885 |
| US-20030119666-A1 | Catalyst for producing both end-hydroxyl group-terminated diols, process for producing the catalyst, process for producing the diols by using the catalyst, and both end-hydroxyl group-terminated diols obtained by the process | ADH1C, ADH1A, EPHX2 | TP53 4146/4885KDM4E 545/4885GMNN 841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.